Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-08-07
2007-08-07
Devi, S. (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C530S350000, C530S300000, C530S825000
Reexamination Certificate
active
11414278
ABSTRACT:
The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicitChlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection byChlamydiaandChlamydiophila.
REFERENCES:
patent: 4267170 (1981-05-01), Seawell
patent: 4271146 (1981-06-01), Seawell
patent: 5242686 (1993-09-01), Chu et al.
patent: 5656271 (1997-08-01), MacDonald et al.
patent: 5716793 (1998-02-01), MacDonald et al.
patent: 5725863 (1998-03-01), Daniels et al.
patent: 5770714 (1998-06-01), Agabian et al.
patent: 5821055 (1998-10-01), Agabian et al.
patent: 5840297 (1998-11-01), MacDonald et al.
patent: 5972350 (1999-10-01), Atherton et al.
patent: 7105171 (2006-09-01), Stephens et al.
patent: WO 94/06827 (1994-03-01), None
patent: WO 96/31236 (1996-10-01), None
patent: WO 97/41889 (1997-11-01), None
patent: WO 98/02546 (1998-01-01), None
patent: WO 98/10789 (1998-03-01), None
patent: WO 98/58953 (1998-12-01), None
patent: WO 99/10005 (1999-03-01), None
patent: WO 99/28475 (1999-06-01), None
patent: WO 9928475 (1999-06-01), None
patent: WO 0156605 (2001-08-01), None
Allen, et al. “A single peptide from the major outer membrane protein of Chlamydia trachomatis elicits T cell help for the production of antibodies to protective determinants”, The Journal of Immunology vol. 147(2): 674-679 (1991).
Bavoil, et al. “Role of disulfide bonding in outer membrane structure and permeability in Chlamydia trachomatis”, Infection and Immunity vol. 44(2): 479-485 (1984).
Berman, et al. “Recommendations for the prevention and management of Chlamydia trachomatis infections”, The Morbidity and Mortality Weekly Report vol. 42(RR-12): 1-102 (1993).
Caldwell, et al. “Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis”, Infection and Immunity vol. 31(3): 1161-1176 (1981).
Everett, et al. “Architecture of the cell envelope of Chlamydia psittaci 6BC”, Journal of Bacteriology vol. 177(4): 877-882 (1995).
Fan, et al. “Antigen conformation dependence of Chlamydia trachomatis infectivity neutralization”, The Journal of Infectious Diseases vol. 176: 713-721 (1997).
Filip, et al. “Solubilization of the cytoplasmic membrane of Escherichia coli by the Ionic detergent sodium-lauryl sarcosinate”, Journal of Bacteriology vol. 115(3): 717-722 (1973).
Iliffe-Lee, et al. “Regulation of carbon metabolism in Chlamydia trachomatis”, Molecular Microbiology vol. 38(1): 20-20 (2000).
Ivens, et al. “A physical map of the Leishmania major Friedlin genome”, Genome Research vol. 8(2): 135-145 (1998).
Kalman, et al. “Comparative genomes of Chlamydia pneumoniae and Chlamydia trachomatis”, Nature Genetics vol. 21: 385-389 (1999).
Kubo, et al. “Characterization and functional analysis of PorB, a Chlamydia porin and neutralizing target”, Molecular Microbiology vol. 38(4): 772-780 (2000).
Moulder, et al. “Interaction of Chlamydiae and host cells in vitro”, Microbiological Reviews vol. 55(1): 143-190 (1991).
Newhall, et al. “Biosynthesis and disulfide cross-linking of outer membrane components during the growth cycle of Chlamydia trachomatis”, Infection and Immunity vol. 55(1): 162-168 (1987).
Read, et al. “Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39”, Nucleic Acids Research vol. 28(6): 1397-1406 (2000).
Sanchez-Campillo, et al. “Identification of immunoreactive proteins of Chlamydia trachomatis by western blot analysis of a two-dimensional electrophoresis map with patient sera”, Electrophoresis vol. 20: 2269-2279 (1999).
Sardinia, et al. “Developmental regulation of the cysteine-rich outer-membrane proteins of murine Chlamydia trachomatis”Journal of General Microbiology vol. 134: 997-1004 (1988).
Stephens, et al. “High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis”, J. Exp. Med. vol. 167: 817-831 (1988).
Stephens, et al. “Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis”, Science vol. 282: 754-759 (1998).
Stephens, et al. “Antigen Variation of Chlamydia trachomatis”, In J.W. Moulder (ed.), Intracellular Parasitism, CRC Press, Boca Raton, pp. 51-62.
Su, et al. “Protective efficacy of a parentally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: Sertum neutralizing IgG antibodies do not protect against chlamydial genital tract infection”, Vaccine vol. 13(11): 1023-1032 (1995).
Thylefors, et al. “Global data on blindness”, Bulletin of World Health Organization vol. 73(1): 115-121 (1995).
Tuffrey, et al. “Heterotrophic protection of mice against Chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein”, Journal of Gen Microbiology vol. 138: 1707-1715 (1992).
Wyllie, et al. “The major outer membrane protein of Chlamydia psittaci functions as a porin-like ion channel”, Infection and Immunity vol. 66(11): 5202-5207 (1998).
Burgess et al. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue.J. Cell Biol. 1990, 111:2129-2138.
Bowie, et al. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science 1990, 247: 1306-1310.
Lazar et al. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Mol. Cellular Biol. 1988, 8: 1247-1252.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000, 18: 34-39.
GenBank Accession No. AAC68308 published Oct. 30, 2000.
GenBank Accession No. AEO01342 AE001273 published Oct. 30, 2000.
GenBank Accession No. H71479 published Oct. 8, 1999.
GenBank Accession No. NP—225049 published Sep. 10, 2001.
GenBank Accession No. CAC44728 published Jul. 25, 2001.
GenBank Accession No. H81742 published May 11, 2000.
GenBank Accession No. AAF38966 published May 26, 2000.
GenBank Accession No. NP—220232 published Sep. 10, 2001.
GenBank Accession No. P38006 published Aug. 20, 2001.
GenBank Accession No. NP—296470 published Oct. 2, 2001.
GenBank Accession No. Q9PLL3 published Oct. 16, 2001.
GenBank Accession No. AAO67537, Mar. 27, 2003.
GenBank Accession No. AAO67531, Mar. 27, 2003.
GenBank Accession No. AAO67530, Mar. 27, 2003.
GenBank Accession No. NP—220232, May 19, 2003.
GenBank Accession No. NP—296470, Aug. 1, 2003.
GenBank Accession No. NP—829774, Aug. 1, 2003.
GenBank Accession No. NP—225049, Dec. 10, 2002.
GenBank Accession No. NP—877155, Jul. 25, 2003.
Kawa Diane
Stephens Richard S.
Bozicevic Field & Francis LLP
Devi S.
Francis Carol L.
The Regents of the University of California
LandOfFree
Porin B (PorB) as a therapeutic target for prevention and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Porin B (PorB) as a therapeutic target for prevention and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Porin B (PorB) as a therapeutic target for prevention and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3834260